Tagged: precision-medicine
30 results
Alpha-9 Oncology
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company engineering bespoke, tumor-targeting molecules that deliver alpha- and beta-emitting isotopes directly to cancer cells while sparing healthy tissue. Spun out of the University of British Columbia and BC Cancer in 2019 and now headquartered in Boston with research operations in Vancouver, the company iteratively optimizes each part of a radiopharmaceutical - binder, linker, chelator and radioisotope - to build a pipeline of paired imaging and therapy candidates. Backed by $258M in total funding, including a $175M Series C in 2024, Alpha-9 aims to expand precision radiotherapy across validated oncology targets.
Atavistik Bio
Atavistik Bio is a Cambridge, Massachusetts clinical-stage biotechnology company that discovers precision allosteric small-molecule medicines. Its proprietary AMPS (Atavistik Metabolite-Protein Screening) platform, paired with an AI-enabled discovery engine, uses natural metabolites as bait to reveal hidden allosteric pockets on disease-driving proteins that conventional drug discovery cannot reach. The company is advancing an oral AKT1-selective inhibitor for hereditary hemorrhagic telangiectasia (HHT) and a JAK2 V617F mutant-selective program for myeloproliferative neoplasms (MPNs).
Embleema
Embleema is a New York- and France-based healthcare technology company that builds a unified real-world data and evidence platform for clinical research. It aggregates clinical, genomic, and patient-reported data from electronic medical records, wearables, biospecimens, and patient apps into regulatory-grade datasets, and uses no-code protocol tools plus dynamic consent to help pharmaceutical sponsors, research sites, and patient groups run non-interventional and Phase IV studies faster and at lower cost. Founded in 2017 by Robert Chu, the company started with a patient-driven health blockchain and its analytics stack has been used by the FDA for genomic regulatory review.
Indi Molecular
Indi Molecular is a Culver City, California biotech developing a synthetic alternative to antibodies called Protein Catalyzed Capture (PCC) agents - small, stable cyclic peptides built with click chemistry that bind protein targets with antibody-like specificity while behaving like small-molecule drugs. Spun out of Caltech chemist James Heath's lab in 2013, the company applies its platform to targeted oncology therapeutics and PET imaging agents, aiming to reach targets long considered undruggable, including KRAS G12D pancreatic cancer and ovarian cancer.
PIC Therapeutics
PIC Therapeutics is a Natick, Massachusetts biotechnology company developing small-molecule precision medicines that target cancer at the level of protein translation. Rather than chasing individual oncogenes one at a time, PIC modulates the Pre-Initiation Complex (PIC) and the translation factor eIF4E - a convergence point for many oncogenic signaling pathways - to selectively shut down the production of cancer-driving proteins while sparing healthy cells. Founded on the research of Harvard structural biologist Gerhard Wagner and led by CEO Katherine Bowdish, the company is advancing an allosteric eIF4E modulator toward first-in-human studies in drug-resistant metastatic breast cancer, backed by a $35M Series A led by OrbiMed.
Complete Genomics
Complete Genomics is a San Jose-based life-science technology company and the Americas arm of MGI. Founded in 2005 as a pioneer of affordable whole-human-genome sequencing, it develops and sells next-generation sequencing instruments, reagents, and analysis software built on its proprietary PCR-free DNBSEQ (DNA nanoball) technology. The company aims to drive down the cost of sequencing - from the landmark $5,000 genome to sub-$100 - and supplies researchers, clinical labs, and biotech companies with a full workflow spanning sample prep, library construction, sequencing, and data analysis.
Siolta Therapeutics
Siolta Therapeutics is a clinical-stage biopharmaceutical company spun out of UCSF that develops defined-consortia live biotherapeutic products to prevent and treat diseases rooted in a disrupted microbiome. Its lead program, STMC-103H, is an oral multi-strain therapy aimed at preventing atopic diseases such as atopic dermatitis and food allergy in newborns, built on the company's proprietary Precision Symbiotics Platform.
Niamh O'Hara
Niamh O'Hara is the co-founder and CEO of Biotia, a New York healthtech company that pairs next-generation DNA sequencing with AI to identify pathogens causing hard-to-diagnose infections. An evolutionary biologist by training, she spun the company out of Cornell Tech with Weill Cornell geneticist Christopher Mason, runs a CLIA-certified metagenomics lab in Long Island City, and is building what she calls a global microbial sequence database to catch outbreaks before they spread.
CatenaBio
CatenaBio is a UC Berkeley spinout building a next-generation bioconjugation platform for targeted cancer therapies. Its proprietary CysTyr platform uses an engineered enzyme, Catenase, to forge a site-specific bond between cysteine and tyrosine residues (the C-Y Bond) using only native amino acids. This lets the company attach multiple different drug payloads to a single antibody, producing Multi-Payload Conjugates (MPCs) designed to overcome tumor resistance where conventional single-payload ADCs fall short.
Sentieon
Sentieon builds ultra-fast, highly accurate software for analyzing DNA and RNA sequencing data. Its pipelines - DNAseq, DNAscope, TNseq, and TNscope - replace the open-source GATK workflow with matching or better accuracy while running many times faster on ordinary CPUs, no specialized hardware required. Founded in 2014 and based in the Bay Area, the company has won top honors in multiple precisionFDA and DREAM challenges, and its tools are used by pharma, clinical labs, sequencing platform makers, and genomics researchers worldwide to turn raw reads into trustworthy variant calls quickly and cheaply.
John Ramunas
John Ramunas, PhD, is the Co-Founder and CEO of Rejuvenation Technologies Inc., a Mountain View, CA biotechnology company pioneering mRNA-based telomere extension therapy to reverse cellular aging. A serial entrepreneur turned neuroscientist, Ramunas spent his PhD at Stanford's Baxter Laboratory for Stem Cell Biology inventing the first safe, nonimmunogenic TERT mRNA drug - a technology now protected by 50+ patents. His company, backed by Khosla Ventures and Y Combinator, is advancing a pipeline targeting fatal orphan diseases including idiopathic pulmonary fibrosis and liver cirrhosis, with the long-term vision of a single therapy taken every few years to prevent age-related disease.
Jun Ye
Jun Ye is the co-founder, president and CEO of Sentieon, a Mountain View bioinformatics company whose variant-calling software has swept the precisionFDA Truth and Consistency Challenges. A Stanford-trained electrical engineer with more than 50 U.S. patents, he previously co-founded Brion Technologies (acquired by ASML in 2006) and Founton Technologies (acquired into Alibaba in 2012), and taught at Stanford as a consulting professor for fourteen years.
Laura E. Benjamin
Laura E. Benjamin is the CEO and President of Myris Therapeutics, a Pittsburgh-based biotech building ultra-high DAR antibody-drug conjugates that fuse polymer chemistry with cancer biologics. A molecular biologist by training, she has moved from Harvard pathology labs to Eli Lilly oncology leadership to two CEO chairs - most recently steering OncXerna through more than $100 million in clinical-stage financing before taking the helm at Myris in 2024.
Arima Genomics
Arima Genomics is a Carlsbad, California biotech commercializing Hi-C technology - sequencing methods that reveal the 3D structure of the genome. Its research kits help scientists assemble chromosome-scale genomes and study chromatin architecture, while its clinical brand Aventa Genomics turns the same proximity-ligation chemistry into FFPE-friendly cancer tests for fusions, rearrangements, and other structural variants conventional NGS often misses.
Plexium
Plexium is a San Diego precision medicine company designing small-molecule protein degraders - monovalent direct degraders and molecular glues - that switch off disease-driving proteins traditionally considered undruggable. Its DELTA Discovery platform runs ultra-high-throughput cell-based screening to find and optimize new degrader chemistry across cancer and neurological disease.
Trace Neuroscience
Trace Neuroscience is a South San Francisco biopharmaceutical company developing genomic medicines for neurodegenerative diseases, starting with ALS. Its lead program, TRCN-1023, is an antisense oligonucleotide designed to restore UNC13A protein function - a target genetically validated in roughly 97% of people living with ALS - by correcting the faulty RNA splicing caused by TDP-43 dysfunction. The company launched in November 2024 with a $101 million Series A led by Third Rock Ventures and entered the clinic in 2026.
Jahangir Mohammed
Jahangir Mohammed is a serial entrepreneur and inventor who built Jasper Technologies into the world's largest IoT platform - sold to Cisco for $1.4 billion in 2016 - then turned his attention to metabolic disease. As Founder and CEO of Twin Health, he is using AI-powered whole-body digital twin technology to reverse chronic conditions like Type 2 diabetes, with clinical results published in the New England Journal of Medicine Catalyst showing 71% of participants achieving A1C below 6.5% while eliminating most medications. Twin Health has raised $335 million total and reached a $950 million valuation in 2025.
Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company based in San Francisco that develops targeted small-molecule therapies for ER+/HER2- metastatic breast cancer and other women's cancers. Its lead candidate, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist and selective ER degrader now in two Phase 3 trials, while a second program, OP-3136, is a KAT6 inhibitor in Phase 1. Olema's bet is that better-designed oral endocrine therapy can overcome the resistance that limits today's standard of care.
PointCross Life Sciences
PointCross Life Sciences is a Foster City, California software and services company that turns the messy data of drug development into FDA-ready submissions. Through its XBIOM platform and eDataValidator, it standardizes nonclinical and clinical study data to CDISC SEND, SDTM and ADaM formats, runs a Hadoop-based data repository for sponsors, and supplies the U.S. FDA itself with the software reviewers use to read nonclinical submissions. The company quietly powers roughly a quarter of all FDA SEND submissions.
Avelos Therapeutics
Avelos Therapeutics is a Seoul-based clinical-stage oncology biotech founded in 2021 that designs small-molecule drugs for 'undruggable' cancer targets using synthetic lethality, DNA damage response (DDR), and cell-cycle biology. Its lead program, AD1208, is a first-in-class oral MASTL kinase inhibitor now in a Phase 1/2a solid-tumor trial. Backed by KRW 30 billion (~$21.7M) across seed, Series A, and a 2024 Series B, the roughly nine-person team is building a biomarker-driven pipeline of four anti-cancer candidates aimed at a future KOSDAQ listing.
Cajal Therapeutics
Cajal Therapeutics (originally launched as Cajal Neuroscience) is a Seattle biotechnology company developing novel medicines to restore biological homeostasis, with a focus on neurodegenerative diseases, anemias of inflammation, and iron-related disorders. Built on a platform that pairs integrative human genetics, high-throughput functional genomics, and industrialized whole-brain imaging with deep neuroscience expertise, the company aims to systematically validate disease targets at unprecedented scale and translate them into small molecule and RNA therapeutics. It launched in November 2022 with a $96 million Series A and counts a roster of celebrated neuroscientists among its co-founders.
Delphia Therapeutics
Delphia Therapeutics is a Cambridge, Massachusetts biotech pioneering a new field of cancer biology it calls activation lethality - the idea that cancer cells with oncogenic mutations live dangerously close to the upper limit of how much pathway activity they can tolerate, and can be pushed past it. Rather than blocking cancer signals like most drugs, Delphia designs targeted activators that overload cancer's stress pathways until the cell dies, aiming for durable benefit and a way around drug resistance. Founded in 2024 by Kevin Marks, Bill Sellers and Mike Dillon, it launched with a $67 million Series A led by GV, Nextech Invest, Polaris Innovation Fund and Alexandria Venture Investments.
TORL BioTherapeutics LLC
TORL BioTherapeutics is a clinical-stage biopharmaceutical company in Culver City, California developing antibody-based cancer therapies, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Built on discoveries from the UCLA laboratory of Dennis Slamon - the scientist behind Herceptin and Ibrance - TORL is advancing a pipeline against novel cancer targets such as Claudin 6, Claudin 18.2, CDH17, and DLK1. Its lead program, TORL-1-23 (ixotatug vedotin), a CLDN6-targeted ADC, is in pivotal trials for platinum-resistant ovarian cancer. The company has raised over $450 million across multiple rounds, including a $96 million Series C in October 2025.
Treeline Biosciences
Treeline Biosciences is a Watertown, Massachusetts biotech founded in 2021 by Loxo Oncology founder Josh Bilenker and former Novartis oncology head Jeff Engelman. It pairs in-house wet-lab R&D with leading-edge computational tools to invent cancer medicines reliably and repeatedly, choosing targets by what the technology can reach rather than by therapeutic fashion. After operating largely in stealth, Treeline has raised more than $1.1 billion and moved three programs - a BCL6 degrader, a pan-KRAS inhibitor, and an EZH2 inhibitor - into Phase 1 trials. In June 2026 it agreed to go public through an all-stock reverse merger with Standard BioTools, with the combined company set to trade on Nasdaq as 'TRLN'.
Triveni Bio
Triveni Bio is a clinical-stage biotechnology company in Watertown, Massachusetts building first-in-class antibody therapeutics for immunological and inflammatory (I&I) diseases. Born from the 2023 merger of Amagma Therapeutics and Modify Therapeutics, the company pairs a genetics-informed approach with advanced antibody engineering to target root-cause biology rather than just downstream inflammation. Its lead program, TRIV-509, is a half-life-extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7) and is in a global Phase 2 proof-of-concept study for moderate-to-severe atopic dermatitis. Backed by roughly $223M across Series A and Series B rounds, Triveni aims to repair the skin barrier and break what it calls efficacy ceilings in dermatology and beyond.
Vesalius Therapeutics
Vesalius Therapeutics is a Cambridge, Massachusetts biotech founded by Flagship Pioneering that aims to reconceptualize how common diseases are understood and treated. Its premise: illnesses that drive roughly 90% of human disease burden are not single conditions but constellations of genetically and biologically distinct diseases. Vesalius uses AI, human genetics and genomics, and patient-derived iPSC cell models to spot hidden clinical patterns, trace them to causal gene circuits, and discover novel drug targets for conditions like Parkinson's, heart failure, type 2 diabetes, and Alzheimer's.
Crossbow Therapeutics, Inc.
Crossbow Therapeutics is a Cambridge, Massachusetts biotechnology company building a new class of cancer immunotherapies. Its T-Bolt platform engineers TCR-mimetic antibodies - T-cell engagers that recognize tiny peptide fragments displayed on a cancer cell's surface (peptide-HLA complexes), opening up intracellular proteins that conventional antibodies cannot reach. The lead program, CBX-250, is a first-in-class T-cell engager in a Phase 1 trial for relapsed or refractory myeloid malignancies. Backed by more than $157M in venture funding, Crossbow aims to expand the universe of targetable cancer antigens.
Helix
Helix is a San Mateo-based population genomics company that helps health systems, life sciences companies, and public health organizations weave genomic data into everyday patient care. Built around its proprietary Exome+ assay and the first FDA-authorized whole exome sequencing platform, Helix powers large-scale precision health programs at partners like Mayo Clinic and Renown Health, with a research network spanning hundreds of thousands of sequenced participants.
Mirador Therapeutics
Mirador Therapeutics is a San Diego precision-medicine company building first- and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases. Its Mirador360 engine fuses human genetics, multi-modal patient data, AI and advanced analytics to find novel targets, design combination therapies and identify the patients most likely to respond. Founded in 2024 by the former Prometheus Biosciences leadership team, Mirador launched with more than $400 million and has since raised over $650 million total.
Paradigm4
Paradigm4 builds scientific data management and analytics software for the life sciences. Its flagship REVEAL platform and SciDB array database let pharma, biotech, and research institutions integrate and analyze massive multimodal datasets - genomics, multi-omics, imaging, clinical records, wearables, and environmental data - to find biomarkers and validate drug targets. Co-founded in 2010 by entrepreneur Marilyn Matz and Turing Award-winning MIT professor Michael Stonebraker, the company is based in Waltham, Massachusetts.